Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-05-23
2008-08-19
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S234500, C514S252140, C514S252190, C514S256000, C514S269000, C514S275000, C514S293000, C514S303000, C514S314000, C514S318000, C514S322000, C514S338000, C514S364000, C514S375000, C514S395000, C540S578000, C544S122000, C544S124000, C544S324000, C544S330000, C544S331000, C544S333000, C546S082000, C546S118000, C546S167000, C546S193000, C546S199000, C546S271700, C546S273100, C546S273400, C548S143000, C548S222000, C548S304700, C548S305100, C548S308100
Reexamination Certificate
active
07414046
ABSTRACT:
The present invention relates to compounds of the formula I:or a pharmaceutically acceptable derivative or prodrug thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammala. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.
REFERENCES:
patent: 4174400 (1979-11-01), Mrozik
patent: 4338315 (1982-07-01), Paget et al.
patent: 4401817 (1983-08-01), Paget et al.
patent: 4512998 (1985-04-01), Nafissi-Varchei
patent: 5529998 (1996-06-01), Habich et al.
patent: A-0385850 (1990-09-01), None
patent: A-0535521 (1993-04-01), None
patent: 0 738 726 (1996-10-01), None
patent: 1 055 668 (2000-11-01), None
patent: 01 258670 (1989-10-01), None
patent: WO 99/35155 (1999-07-01), None
patent: WO 00/49015 (2000-08-01), None
patent: WO 00/71522 (2000-11-01), None
Snyder et al., PubMed Abstract (J. Med. Liban. 48(4):208-14) Jul.-Aug. 2000.
Singh et al., CAPLUS Abstract 112:198195, 1990.
U.S. Appl. No. 10/015,332, filed Dec. 12, 2001, Anne-Laure Grillot, et al.
Singh, S.K., et al., “Studies in antiparasitic agents: Part 13—Synthtesis of 4-aryl-2-substitutedamino-thiazoles as potential anthelmintics,”Indian J. Chem., 28B(9):786-789 (1989).
Beers, M. H., and Berkow, R., “The Merck Manual of Diagnosis and Therapy”, 7thEdition, Chapter 156—Bacteremia and Septic Shock,Merck Research Laboratories, Whitehouse Station, NJ, pp. 1143-1147 (1999).
Nicolaus B. J. R., “Symbiotic Approach to Drug Design,” Decision Making in Drug Research, pp. 173-186 (1983).
Kus, C., et al., “Synthesis and antimicrobial activities of 5-fluoro-1, 2, 6-trisubstituted benzimidazole carboxamide and acetamide derivatives,” Arch. Pharm. Pharm. Med. Chem. 334(11):361-365 (2001).
Sanchez-Alonzo, R.M. et al., “Piperazine Derivatives of Benzimidazoles as Potential Anthelminthics”, Pharmazie, 44(9), pp. 606-607, 1989.
Badia Michael
Charifson Paul
Grillot Anne-Laure
Liao Yusheng
Stamos Dean
Badia Michael C.
Rao Deepak
Vertex Pharmaceuticals Incorporated
LandOfFree
Gyrase inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gyrase inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gyrase inhibitors and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4009449